Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X9VR
|
|||
| Former ID |
DIB010832
|
|||
| Drug Name |
BGB-324
|
|||
| Synonyms |
BGB-001; SiRNA therapeutic (metastasis cancer), BiobergenBio
Click to Show/Hide
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [1], [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [1] | ||
| Metastatic malignant neoplasm [ICD-11: 2D50-2E09] | Investigative | [3] | ||
| Company |
BergenBio AS
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosine-protein kinase UFO (AXL) | Target Info | . | [3] |
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | VEGFA-VEGFR2 Pathway | |||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.